arvinas_logoART_lg.jpg
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
November 27, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
November 26, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
November 26, 2024 07:00 ET | Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
November 25, 2024 17:35 ET | Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...
Nurix.png
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
November 17, 2024 10:30 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
November 05, 2024 07:00 ET | Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
November 04, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
October 31, 2024 07:30 ET | Kymera Therapeutics, Inc.
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in...
arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 30, 2024 07:00 ET | Arvinas Inc.
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
October 24, 2024 07:00 ET | Kymera Therapeutics, Inc.
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated...